JonesResearch initiated coverage of Mind Medicine (MNMD) with a Buy rating and $61 price target The firm, which anticipates that “strong” clinical data from earlier stages will translate into positive Phase 3 results for lead asset MM120 in generalized anxiety disorder and major depressive disorder, views MindMed as poised to take advantage of current trends favoring the development of psychedelic agents in psychiatry, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNMD:
- Psychedelic: Atai Beckley, Cybin report quarterly earnings
- MindMed’s Earnings Call: Positive Outlook Amid Financial Challenges
- Mind Medicine’s Strong Financial Position and Clinical Progress Drive Buy Rating
- Mind Medicine’s Promising Clinical Progress and Strategic Advancements Justify Buy Rating
- Mind Medicine price target raised to $25 from $16 at Canaccord